Investigación > Cáncer

Señalización Oncogénica y del Desarrollo

Número de publicaciones
127
Buscador de publicaciones
  • Dosil, MA; Mirantes, C; Eritja, N; Felip, I; Navaridas, R; Gatius, S; Santacana, M; Colàs E; Moiola, C; Schoenenberger, JA; Encinas, M; Gari, E; Matias-Guiu, X; Dolcet, X

    Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias

    JOURNAL OF PATHOLOGY 242 152-164. .

    [doi:10.1002/path.4896]

  • Mancikova, V; Montero-Conde, C; Perales-Paton, J; Fernandez, A; Santacana, M; Jodkowska, K; Inglada-Perez, L; Castelblanco, E; Borrego, S; Encinas, M; Matias-Guiu, X; Fraga, M; Robledo, M

    Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors

    CLINICAL CANCER RESEARCH 23 1334-1345. .

    [doi:10.1158/1078-0432.CCR-16-0947]

  • Eritja, N; Chen, BJ; Rodriguez-Barrueco, R; Santacana, M; Gatius, S; Vidal, A; Marti, MD; Ponce, J; Bergada, L; Yeramian, A; Encinas, M; Ribera, J; Reventos, J; Boyd, J; Villanueva, A; Matias-Guiu, X; Dolcet, X; Llobet-Navas, D

    Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer

    Autophagy 13 608-624. .

    [doi:10.1080/15548627.2016.1271512]

  • Eritja, N; Yeramian, A; Chen, BJ; Llobet-Navas, D; Ortega, E; Colas, E; Abal, M; Dolcet, X; Reventos, J; Matias-Guiu, X

    Endometrial Carcinoma: Specific Targeted Pathways

    Advances in Experimental Medicine and Biology 943 149-207. .

    [doi:10.1007/978-3-319-43139-0_6]

  • Torremade, N; Bozic, M; Panizo, S; Barrio-Vazquez, S; Fernandez-Martin, JL; Encinas, M; Goltzman, D; Arcidiacono, MV; Fernandez, E; Valdivielso, JM

    Vascular Calcification Induced by Chronic Kidney Disease Is Mediated by an Increase of 1 alpha-Hydroxylase Expression in Vascular Smooth Muscle Cells

    JOURNAL OF BONE AND MINERAL RESEARCH 31 1865-1876. .

    [doi:10.1002/jbmr.2852]

  • Mirantes, C; Dosil, MA; Eritja, N; Felip, I; Gatius, S; Santacana, M; Matias-Guiu, X; Dolcet, X

    Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias

    EUROPEAN JOURNAL OF CANCER 63 74-87. .

    [doi:10.1016/j.ejca.2016.04.019]

  • Yeramian A; García V; Bergadà L; Domingo M; Santacana M; Valls J; Martinez-Alonso M; Carceller JA; Cussac AL; Dolcet X; Matias-Guiu X

    Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-kappa B Pathway in Endometrial Cancer

    MOLECULAR IMAGING AND BIOLOGY 18 545-556. .

    [doi:10.1007/s11307-015-0907-8]

  • Gou-Fabregas, M; Macia, A; Anerillas, C; Vaquero, M; Jove, M; Jain, S; Ribera, J; Encinas, M

    7-dehydrocholesterol efficiently supports Ret signaling in a mouse model of Smith-Opitz-Lemli syndrome

    SCIENTIFIC REPORTS 6 28534-28534. .

    [doi:10.1038/srep28534]

  • Santacana M; Coronado P; Matias-Guiu X; Romero I; Casado A; Gil-Moreno A; Dosil MA; Mota A; Moreno-Bueno G; Dolcet X; Llombart-Cussac A; Poveda A

    Biological Effects of Temsirolimus on the mTOR Pathway in Endometrial Carcinoma: A Pharmacodynamic Phase II Study.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER -. .

    [doi:10.1097/IGC.0000000000000715]

  • Fuste, NP; Fernandez-Hernandez, R; Cemeli, T; Mirantes, C; Pedraza, N; Rafel, M; Torres-Rosell, J; Colomina, N; Ferrezuelo, F; Dolcet, X; Gari, E

    Cytoplasmic cyclin D1 regulates cell invasion and metastasis through the phosphorylation of paxillin

    Nature Communications 7 11581-11581. .

    [doi:10.1038/ncomms11581]

  • Fuste, NP; Castelblanco, E; Felip, I; Santacana, M; Fernandez-Hernandez, R; Gatius, S; Pedraza, N; Pallares, J; Cemeli, T; Valls, J; Tarres, M; Ferrezuelo, F; Dolcet, X; Matias-Guiu, X; Gari, E

    Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer

    Oncotarget 7 26979-26991. .

    [doi:10.18632/oncotarget.8876]

  • Yeramian, A; Vea, A; Benitez, S; Ribera, J; Domingo, M; Santacana, M; Martinez, M; Maiques, O; Valls, J; Dolcet, X; Vilella, R; Cabiscol, E; Matias-Guiu, X; Marti, RM

    2-phenylethynesulphonamide (PFT-) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels

    PIGMENT CELL & MELANOMA RESEARCH 29 352-371. .

    [doi:10.1111/pcmr.12472]